EUVIMEDEUVIMED entdecken
Crossref

CAR T-Cell Therapy For Refractory Autoimmune Diseases: Rethinking Immune Tolerance Through Cellular Engineering

Shehzma Pirani

International Journal of Drug Delivery Technology · 11.04.2026 · 16 (7s)

DOI: 10.25258/ijddt.16.7s.102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 11.04.2026. Verfasst von Shehzma Pirani.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For decades, clinicians managing refractory autoimmune diseases have operated within a frustrating therapeutic ceiling — escalating immunosuppression that controls rather than cures, and biologics that must be sustained indefinitely at the cost of infection, toxicity, and diminishing returns. Chimeric antigen receptor (CAR) T-cell therapy, developed originally to hunt down malignant B cells in haematological cancers, is now being turned toward this unmet need with results that few in the field anticipated so soon. Early clinical series — small in number but striking in consistency — show that a single infusion of CD19-directed CAR T cells can bring patients with refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM) into drug-free remission. Some have remained off all immunosuppression for more than two years. This is not incremental progress. It is a different kind of intervention entirely — one that appears to work not by suppressing the immune system indefinitely, but by depleting its autoreactive components and allowing something resembling a fresh immunological start. This review traces the biology behind that possibility, examines what the clinical data actually show across individual disease contexts, considers how the technology is evolving through next-generation engineering, and confronts the real barriers — manufacturing, access, durability, resistance — that stand between early-phase promise and genuine clinical practice. As of mid-2025, 119 registered global trials are underway, the vast majority in Phase I. The science is moving fast; the standards it must meet are appropriately high.

Zitieren

APA

Pirani, S. (2026). CAR T-Cell Therapy For Refractory Autoimmune Diseases: Rethinking Immune Tolerance Through Cellular Engineering. International Journal of Drug Delivery Technology, 16(7s). https://doi.org/10.25258/ijddt.16.7s.102

Vancouver

Pirani S. CAR T-Cell Therapy For Refractory Autoimmune Diseases: Rethinking Immune Tolerance Through Cellular Engineering. International Journal of Drug Delivery Technology. 2026;16(7s). doi:10.25258/ijddt.16.7s.102

BibTeX
@article{Pirani2026,
  author = {Pirani, Shehzma},
  title = {CAR T-Cell Therapy For Refractory Autoimmune Diseases: Rethinking Immune Tolerance Through Cellular Engineering},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {7s},
  doi = {10.25258/ijddt.16.7s.102}
}
Kostenlos starten →